Drug Trial Radar · NCT06666491
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Nov 13, 2024
Primary completion
May 14, 2027
Study completion May 14, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.
Conditions
- Malaria, Vivax
Interventions
TafenoquineDrug
A single dose of TQ will be administered orally on Day 1 or Day 2.
PrimaquineDrug
A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).
ChloroquineDrug
A single dose of CQ will be administered orally, daily, on Days 1 to 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants remaining recurrence-free during the 6 months post-treatment and have a negative blood smear at the Month 6 (end of study [EOS]) visitTime frame: Up to Month 6
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Ahmedabad, India · Recruiting
GSK Investigational Site
Bikaner, India · Recruiting
GSK Investigational Site
Kolkata, India · Recruiting
GSK Investigational Site
Mumbai, India · Recruiting
GSK Investigational Site
Surat, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.